Pro-malignant properties of STAT3 during chronic inflammation
Pro-malignant properties of STAT3 during chronic inflammation |
|
https://doi.org/10.18632/oncotarget.482
Marco Demaria,
and Valeria Poli
|
| 359-360 |
Attacking tumor cells with a dual ligand for innate immune receptors
Attacking tumor cells with a dual ligand for innate immune receptors |
|
https://doi.org/10.18632/oncotarget.484
Johan Garaude,
and J. Magarian Blander
|
| 361-362 |
Accelerating cancer evolution: a dark side of SIRT1 in genome maintenance
Accelerating cancer evolution: a dark side of SIRT1 in genome maintenance |
|
https://doi.org/10.18632/oncotarget.487
WenYong Chen
|
| 363-364 |
Targeting Cancer Gene Therapy with Magnetic Nanoparticles
Targeting Cancer Gene Therapy with Magnetic Nanoparticles |
|
https://doi.org/10.18632/oncotarget.490
Charles Li,
Linda Li,
and Andrew C. Keate
|
| 365-370 |
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment |
|
https://doi.org/10.18632/oncotarget.477
Alberto M. Martelli,
Francesca Chiarini,
Camilla Evangelisti,
Alessandra Cappellini,
Francesca Buontempo,
Daniela Bressanin,
Milena Fini,
and James A. McCubrey
|
| 371-394 |
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts |
|
https://doi.org/10.18632/oncotarget.488
Sílvia Cufí,
Bruna Corominas-Faja,
Alejandro Vazquez-Martin,
Cristina Oliveras-Ferraros,
Joan Dorca,
Joaquim Bosch-Barrera,
Begoña Martin-Castillo,
and Javier A Menendez
|
| 395-398 |
Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation
Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation |
|
https://doi.org/10.18632/oncotarget.473
Veronique Mathieu,
Christine Pirker,
Wolfgang M Schmidt,
Sabine Spiegl-Kreinecker,
Daniela Lötsch,
Petra Heffeter,
Balazs Hegedus,
Michael Grusch,
Robert Kiss,
and Walter Berger
|
| 399-413 |
Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance
Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance |
|
https://doi.org/10.18632/oncotarget.519
Daniel J. O'Shannessy,
Gordon Yu,
Robert Smale,
Yao-Shi Fu,
Sunil Singhal,
Robert P. Thiel,
Elizabeth B. Somers,
and Anil Vachani
|
| 414-425 |
Properties of Mechano-Transduction via Simulated Microgravity and its Effects on Intracellular Trafficking of VEGFR’s
Properties of Mechano-Transduction via Simulated Microgravity and its Effects on Intracellular Trafficking of VEGFR’s |
|
https://doi.org/10.18632/oncotarget.472
Andrew Puca,
Giuseppe Russo,
and Antonio Giordano
|
| 426-434 |
Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling Glucose regulatory protein 78 and AMPK
Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling Glucose regulatory protein 78 and AMPK |
|
https://doi.org/10.18632/oncotarget.483
Prabodh K. Kandala,
and Sanjay K. Srivastava
|
| 435-449 |
Methylation profiling of normal individuals reveals mosaic promoter methylation of cancer-associated genes.
Methylation profiling of normal individuals reveals mosaic promoter methylation of cancer-associated genes. |
|
https://doi.org/10.18632/oncotarget.480
Lasse S. Kristensen,
Michael P. Raynor,
Ida L. Candiloro,
and Alexander Dobrovic
|
| 450-461 |
On the presence and role of human gene-body DNA methylation
On the presence and role of human gene-body DNA methylation |
|
https://doi.org/10.18632/oncotarget.497
Daudi Jjingo,
Andrew B. Conley,
Soojin V. Yi,
Victoria V. Lunyak,
and I. King Jordan
|
| 462-474 |
Singular v Dual Inhibition of SNF2L and Its Isoform, SNF2LT, Have Similar Effects on DNA Damage but Opposite Effects on the DNA Damage Response, Cancer Cell Growth Arrest and Apoptosis
Singular v Dual Inhibition of SNF2L and Its Isoform, SNF2LT, Have Similar Effects on DNA Damage but Opposite Effects on the DNA Damage Response, Cancer Cell Growth Arrest and Apoptosis |
|
https://doi.org/10.18632/oncotarget.479
Yin Ye,
Yi Xiao,
Wenting Wang,
Jian-Xin Gao,
Kurtis Yearsley,
Quintao Yan,
and Sanford H. Barsky
|
| 475-489 |
BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients |
|
https://doi.org/10.18632/oncotarget.481
Thomas Cluzeau,
Guillaume Robert,
Nicolas Mounier,
Jean Michel Karsenti,
Maeva Dufies,
Alexandre Puissant,
Arnaud Jacquel,
Aline Renneville,
Claude Preudhomme,
Jill Patrice Cassuto,
Sophie Raynaud,
Frederic Luciano,
and Patrick Auberger
|
| 490-501 |
Comprehensive Assessment of Potential Multiple Myeloma Immunoglobulin Heavy Chain V-D-J Intraclonal Variation Using Massively Parallel Pyrosequencing
Comprehensive Assessment of Potential Multiple Myeloma Immunoglobulin Heavy Chain V-D-J Intraclonal Variation Using Massively Parallel Pyrosequencing |
|
https://doi.org/10.18632/oncotarget.469
Renee C. Tschumper,
Yan W. Asmann,
Asif Hossain,
Paul M. Huddleston,
Xiaosheng Wu,
Angela Dispenzieri,
Bruce W. Eckloff,
and Diane F. Jelinek
|
| 502-513 |
